SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies. In November 2020, SynOx acquired from Roche an exclusive worldwide license to emactuzumab, a potentially best-in-class CSF-1R therapeutic antibody. Emactuzumab has a well-tolerated safety profile and showed remarkable efficacy in patients suffering from diffuse tenosynovial giant cell tumour (TGCT), a rare disease that causes significant pain and disability. SynOx is led by an experienced team of industry professionals with a successful track record of developing and bringing products to commercialisation.
Total raised: $156.8M
Investors 2
| Date | Name | Website |
| - | Forbion | forbion.co... |
| 16.06.2022 | GIMV | gimv.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 30.04.2024 | Series B | $75M | Forbion |
| 11.08.2022 | Series A | $37.89M | - |
| 19.11.2020 | Series A | $43.91M | Forbion |
Mentions in press and media 12
| Date | Title | Description |
| 30.04.2024 | SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab | • SynOx is developing emactuzumab - a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibody • Provides flexible loan facility to support additional clinical work and activities to drive its successful registration ... |
| 30.04.2024 | SynOx Therapeutics Raises Up To $35M in Debt Financing | SynOx Therapeutics Limited, a Dublin, Ireland- and Oxford, UK-based late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases, raised up to $35M in Deb... |
| 23.04.2024 | SynOx Therapeutics: Revolutionizing TGCT Treatment with Emactuzumab | SynOx Therapeutics Limited, a clinical biopharmaceutical company, has secured a whopping $75 million in Series B financing to advance the development of Emactuzumab, a groundbreaking monoclonal antibody for the treatment of Tenosynovial Gia... |
| 22.04.2024 | Forbion co-leads $75m Series B Financing in SynOx Therapeutics | •Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures •Funds will be used for pivotal trial of potential best-in-class, next-generation treatment for Tenosynovial Giant Cell Tumour Dublin, Ireland and Oxford, UK, 22 Apri... |
| 22.04.2024 | SynOx Therapeutics Raises $75M in Series B Funding | SynOx Therapeutics, a Dublin, Ireland and Oxford, UK-based late-stage clinical biopharmaceutical company, closed a $75m Series B financing. The round was co-led by Forbion, HealthCap and new investor Bioqube Ventures. As part of the Series ... |
| 01.09.2022 | Emactuzumab designated as an Orphan Medicinal Product in Europe | Dublin, Ireland, 31 August 2022: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company, announces a regulatory update on emactuzumab, in development for the treatment of Tenosynovial Giant ... |
| 12.01.2022 | SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer | Dublin, Ireland, August 3, 2021: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumours (TGCT), today announces th... |
| 19.11.2020 | SynOx Therapeutics raises €37M in Series A Financing | DUBLIN, Nov. 19, 2020 /PRNewswire/ — SynOx Therapeutics Ltd (“SynOx”), a clinical stage bio pharmaceutical company, announces today the closing of a €37 million Series A financing co-led by HealthCap and Medicxi and joined by investors Forb... |
| 19.11.2020 | SynOx raises €37M to advance ex-Roche drug in rare tumor type | SynOx Therapeutics has raised €37 million ($44 million) to advance a drug licensed from Roche. The series A tees SynOx up to build on signs the anti-CSF1R monoclonal antibody improves outcomes in patients with tenosynovial giant cell tumors... |
| - | SynOx Therapeutics raises €37M in Series A Financing | Dublin, Ireland, November 19, 2020 –SynOx Therapeutics Ltd (“SynOx”), a clinical stage biopharmaceutical company, announces today the closing of a €37 million Series A financing co-led by HealthCap and Medicxi and joined by investors Forbio... |
Show more